the guy who was tricking people here with his 10 ids and always posting about the "impressive" growth potential of fusilev,folotyn, zevalin and more so on the "impressive" pipeline including apaz.
I don;t know how many people in this msg board thought that there were actually 10 diff people saying positive things on sppi and purchased or held shares.
and other ids
sts - have you factored the "impressive" growth potential of fusilev, folotyn and not to forget zevalin.
have you factored the "impressive" pipeline including Apaziquone ?
Best is yet to come
you better buy the stock or else you are going to miss buying this undervalued stock..
however, i may sell stock from time to time...its all pre-arranged..nothing to worry. Remember before you put your buy order ""Best is yet to come""
Ben- what do you mean by "minority has less than certain percentage" ?
my larger question is :
Is there any truth in Bluemountain allegation that the"3.9m BBH shares" that voted in favor of SUN recommendations were actually not disinterested ?
If there is truth isn't this a serious matter in the US with all those 13D's filed by sun?
why has the matter not gone anywhere ?
you seem to know more than anyone.
let me ask you this.
Question: If the "BBH shares" (3.9m shares) that voted on lines of SUN(Board) have some connection(relative,friend,business connection, etc) with Sun or Shanghvi, why then Bluemountain or Iszo have not been able to do anything on this matter ?
one would think the matter is pretty serious even in US(not just Israel) considering 13D's filed by Sun indicating their beneficial ownership
- $543m EBITDA
- $1 billion (by 05/30) cash
- 35 ANDA pipeline mostly complex generics requiring clinical studies
- 1 NDA
- Novexatin (2017?)
- Solid growth - last 5 years
- Throwing ton of cash every quarter
how the f can this trade at 10X EBITDA ?
besides its a mystery to know who is making the market here (buyer and seller). The sole mumbai based analyst has $190 ..kal said something like despite challenges he hoped to see growth...but stock refuses to go above $150 with such rock solid fundamentals and cash at $1b. I have not found another stock as cheap and with such solid business as taro.
well, its too little too late! By the time Greg releases his report and his target price, taro would likely be left with 1 shareholder !
cash likely would now be greater than billion dollars. shanghvi said they are looking for acquisitions but valuation is a concern. I am not sure if I would agree. Sun has made 6 acquisitions in the last 3-4 years including 2 dermatology assets: DUSA and merck phase 3 asset.
1)1. Can you please provide
a. Brand value in sales of next 3 year pipeline launches
b. Brand value in sales of next 3 year pipeline para 4
c. Revenue concentration of top 10 products in your 2014 sales- Eg: Prod 1-10% Prod 2 - 5%, etc (No need to name products)
-I am NOT asking for product specific or commercially sensitive info here.
- Perrigo gives this info
Shanghvi said he cannot talk about pipeline
I guess Depressing valuation will continue. Market wants to understand risk and outlook information. Keeping market in dark is not getting to get new investors and depressing valuation will continue
2) Why can't we conduct Annual Investor day and attend Investment Conferences like other companies Mylan, Perrigo, Actavis ?
I guess they talked about Buyback.Not 1 shareholder voiced it is bad for minority because it reduces liquidity , valuation and minority stake as aggregate owner.
its interesting how hard joe works to delete our posts. i wrote a benign post yesterday just consolidating all the ids.....and poof in 10 mins the post was deleted
and who knows 100 other ids
iome70 - what price did you buy shares and why (was it the impressive growth potential of fusilev, zevalin and folotyn or impressive pipeline ..apaz, etc) ? are you still holding it ?
btw, please go to stocksdd blog and it may serve some use for shareholders